Valuation: Celltrion, Inc.

Market Cap 42,81500Cr 2.98TCr 2.59TCr 2.41TCr 2.21TCr 4.18TCr 2,84400Cr 4.24TCr 28TCr 11TCr 1,41600Cr 11TCr 11TCr 4,74700Cr P/E 2026 *
28.4x
P/E 2027 * 24.5x
Enterprise Value 4.48TCr 3.12Cr 2.71Cr 2.52Cr 2.32Cr 4.37Cr 297.49Cr 4.44Cr 30Cr 12Cr 148.1Cr 12Cr 11Cr 496.61Cr EV / Sales 2026 *
8.22x
EV / Sales 2027 * 6.97x
Free-Float
58.02%
Yield 2026 *
0.41%
Yield 2027 * 0.44%
Manager TitleAgeSince
Chief Executive Officer 65 20/03/2015
Chief Executive Officer 42 26/03/2021
President 50 13/02/2026
Director TitleAgeSince
Chairman 68 -
Director/Board Member 61 01/04/2005
Director/Board Member 66 -
Change 5-day change 1-year change 3-year change Capi.($)
-1.40%+2.59%-1.71%+11.28% 4.85TCr
-2.41%-0.90%+403.17%+614.40% 3.99TCr
-1.16%+12.96%+26.45%+5.03% 3.87TCr
-1.88%-3.03%+4.94%+47.52% 3.51TCr
-2.85%-3.92% - - 1.61TCr
-0.21%-4.04%+35.09%+127.95% 1.61TCr
-0.64%+2.65%+1.25%+8.92% 1.36TCr
-1.19%-1.32%-3.32%-34.94% 1.26TCr
-0.90%+2.62%+37.06%+10.96% 1.12TCr
Average -1.40%+0.85%+62.86%+98.89% 2.58TCr
Weighted average by Cap. -1.54%+1.75%+84.09%+133.35%

Financials

2026 *2027 *
Net sales 5,44900Cr 379.11Cr 329.56Cr 306.75Cr 281.63Cr 531.84Cr 36TCr 540.08Cr 3.62TCr 1.42TCr 18TCr 1.42TCr 1.39TCr 60TCr 6,32500Cr 440.03Cr 382.52Cr 356.04Cr 326.89Cr 617.3Cr 42TCr 626.86Cr 4.2TCr 1.65TCr 21TCr 1.65TCr 1.62TCr 70TCr
Net income 1,48500Cr 103.33Cr 90Cr 84Cr 77Cr 144.96Cr 9.86TCr 147.21Cr 985.54Cr 386.79Cr 4.91TCr 388.07Cr 379.55Cr 16TCr 1,76800Cr 123.02Cr 106.94Cr 100Cr 91Cr 172.58Cr 12TCr 175.25Cr 1.17TCr 460.48Cr 5.85TCr 462.01Cr 451.86Cr 20TCr
Net Debt 1,97800Cr 137.59Cr 119.61Cr 111.33Cr 102.21Cr 193.02Cr 13TCr 196.01Cr 1.31TCr 515.03Cr 6.54TCr 516.74Cr 505.39Cr 22TCr 1,26200Cr 88Cr 76Cr 71Cr 65Cr 123.22Cr 8.38TCr 125.13Cr 837.73Cr 328.78Cr 4.17TCr 329.87Cr 322.63Cr 14TCr
Logo Celltrion, Inc.
Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
A